Sign in

You're signed outSign in or to get full access.

John Clarke

Director at Zoomcar Holdings
Board

About John Clarke

Independent director at Zoomcar Holdings since June 2024; finance executive with 40 years in specialty financing, capital markets, and emerging growth offerings. Senior Managing Director at Aegis Capital Corp and SternAegis Ventures since 2021; previously President of H.C. Wainwright & Co, roles at Spencer Trask Ventures, and branch manager at Josephthal, Lyon & Ross. B.S. in Finance from the E. Claiborne Robbins School of Business; resides in New Jersey .

Past Roles

OrganizationRoleTenureCommittees/Impact
Aegis Capital CorpSenior Managing Director2021–present Placement agent for ZCAR financings; received fees and warrants
SternAegis VenturesSenior Managing Director2021–present Associated with capital raising for ZCAR
H.C. Wainwright & CoPresidentPrior to 2021 (noted, no dates) Led offerings in emerging industries
Spencer Trask VenturesSenior rolesPrior (noted, no dates) Venture financing
Josephthal, Lyon & RossBranch ManagerPrior (noted, no dates) Brokerage operations leadership

External Roles

OrganizationRoleTenureNotes
Aegis Capital CorpSenior Managing Director2021–present Aegis designated Clarke to ZCAR’s Board under a one-time right to nominate two independent directors .
SternAegis VenturesSenior Managing Director2021–present Affiliated with Aegis Capital activities.

Board Governance

  • Independence: Determined independent under Nasdaq/Exchange Act Rule 10A-3 .
  • Classified board: Class I (Clarke and Majumdar) through 2027 annual meeting .
  • Committee assignments:
    • April 21, 2025 reconstitution: Compensation Committee (Chair: John Clarke), Audit Committee (Members: Evelyn D’An, John Clarke, Swatick Majumdar), Nominating & Corporate Governance (Chair: Swatick Majumdar; Member: Evelyn D’An) .
    • As of S-1/A (May 12, 2025): Audit Committee members: Evelyn D’An (Chair), John Clarke, Swatick Majumdar .
  • Attendance metrics: Not disclosed in referenced filings.
CommitteeRoleMembers
CompensationChairJohn Clarke (Chair), Evelyn D’An
AuditMemberEvelyn D’An (Chair), John Clarke, Swatick Majumdar
Nominating & Corporate GovernanceSwatick Majumdar (Chair), Evelyn D’An

Fixed Compensation

ElementAmountNotes
Annual Board Cash Retainer ($)75,000
Additional Retainer – Chairman of the Board ($)15,000
Committee Member Retainer – Audit ($)10,000
Committee Member Retainer – Compensation ($)6,000
Committee Member Retainer – Nominating & Corporate Governance ($)4,000
Committee Chair Additional Retainer – Audit ($)10,000
Committee Chair Additional Retainer – Compensation ($)6,000
Committee Chair Additional Retainer – Nominating & Corporate Governance ($)4,000
John Clarke – FY 2025 Director CompensationAmount ($)Description
Fees Earned or Paid in Cash63,750
Option Awards45,890
Total109,640

Performance Compensation

Award TypeValue ($)VestingChange-of-Control Treatment
Initial RSU – Non-Employee Directors300,000 3 years (1/3 on first anniversary; then quarterly), or first anniversary of Closing for initial awards granted immediately following Closing
Additional Initial RSU – Chairman100,000
Annual RSU – Non-Employee Directors100,000
Vesting ConditionContinuous service as director
AccelerationFull acceleration upon change in control

Other Directorships & Interlocks

EntityRelationship to Clarke/BoardTransaction/IssuePotential Conflict/Note
Aegis Capital CorpClarke is Senior Managing Director; Aegis designated Clarke to Board Aegis acted as placement agent for Institutional Offering and Reg D Offering; received cash fees, expense allowances, and placement agent warrants Interlock: Placement agent with ongoing fee/warrant economics while affiliated executive serves on ZCAR Board – governance sensitivity around independence in financing decisions

Expertise & Qualifications

  • Capital markets specialist with several hundred million raised across 100+ offerings; securities licensure including General Securities and Financial & Operations Principal; research analyst supervisory licenses .
  • Financial oversight experience supports Audit/Compensation committee roles .

Equity Ownership

Date (Record)Shares Beneficially OwnedNotes
Nov 21, 2024657 (via exercisable warrants within 60 days)
Dec 30, 2024657 (exercisable warrants within 60 days; <1%)
May 7, 20251,798; <1% of outstanding
  • Section 16 compliance: ZCAR disclosed a late Form 4 filing by Clarke for FY ended Mar 31, 2025 .
  • Shares pledged: Not disclosed.
  • Stock ownership guidelines: Not disclosed.

Insider Trades

Filing DateFormTransaction DateSecurities TransactedSecurityPost-Transaction OwnershipLink
2024-12-03Form 32023-12-28656Warrants to purchase Common Stock0https://www.sec.gov/Archives/edgar/data/1854275/000121390024105052/0001213900-24-105052-index.htm

Note: ZCAR also disclosed Clarke filed a late Form 4 in FY 2025, but the transaction details were not specified in the 10-K .

Governance Assessment

  • Strengths: Independent director with deep capital markets expertise; serves as Compensation Committee Chair and Audit Committee member; independence affirmed under Nasdaq/Rule 10A-3 .
  • Alignment: Director equity program includes meaningful RSU grants with standard vesting and change-of-control acceleration; FY 2025 mix reflects both cash and equity awards (cash $63,750; options $45,890) .
  • Risks/RED FLAGS:
    • Aegis interlock: Clarke’s senior role at Aegis (placement agent receiving fees and warrants) plus Aegis’s designation rights may create perceived conflicts in financing decisions and related-party dynamics; robust Audit Committee oversight of related party transactions is essential .
    • Section 16 timeliness: Late Form 4 filing noted for Clarke, indicating a compliance lapse (minor but noteworthy for governance monitoring) .
  • Attendance and engagement: No explicit meeting attendance rates disclosed; committee reconstitution in April 2025 shows active governance adjustments post-director changes .

Overall, Clarke brings valuable financing expertise and committee leadership. The Aegis relationship warrants heightened scrutiny during capital markets transactions to safeguard board independence and shareholder confidence .